FIGURE 3.

Kaplan–Meier curves for the proportion of participants with primary MN who progressed to the combined endpoint of complete or partial remission (A) or to complete remission considered as a single endpoint (B) in the four subgroups of male or female patients with anti-PLA₂R antibody titer above or below the median considered separately. The highest probability of progressing to the combined endpoint was observed in females with anti-PLA₂R antibody titer below the median. A slightly lower probability of progressing to the combined endpoint was observed in females with anti-PLA₂R antibody titer above the median, whereas the probability crumbled in males with antibody titer below the median. The lowest probability was observed in males with antibody titer above the median. Differences between considered subgroups versus the subgroup of males with antibody titer below the median (reference group) were significant. A similar trend was observed for complete remission, considered as a single endpoint.